loading

Finanzdaten der Relmada Therapeutics Inc-Aktie (RLMD)

Gewinn- und Verlustrechnung
Vierteljährlich
*Alle Zahlen in Millionen
Enddatum des Zeitraums 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30
Periodenlänge 3 Monate 3 Monate 3 Monate 3 Monate 3 Monate
Revenues
-
- - - -
Operating Expenses
43.90%
10.22
18.22 19.08 23.01 18.82
Operating Income/Loss
43.90%
-10.22
-18.22 -19.08 -23.01 -18.82
Nonoperating Income/Loss
46.15%
0.3549
0.659 0.4184 1.2829 1.0507
Income/Loss From Continuing Operations Before Tax
43.81%
-9.8664
-17.56 -18.66 -21.73 -17.77
Income/Loss From Continuing Operations After Tax
43.81%
-9.8664
-17.56 -18.66 -21.73 -17.77
Net Income/Loss
43.81%
-9.8664
-17.56 -18.66 -21.73 -17.77
Preferred Stock Dividends And Other Adjustments
-
- - - -
Attributable To Noncontrolling Interest
-
- - - -
Basic Average Shares
9.15%
33.19
30.41 0.00351 30.17 30.17
Diluted Average Shares
9.15%
33.19
30.41 0.00351 30.17 30.17
Basic Earnings Per Share
48.28%
-0.30
-0.58 -0.62 -0.72 -0.59
Diluted Earnings Per Share
48.28%
-0.30
-0.58 -0.62 -0.72 -0.59
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic
-
- - - -
$38.43
price up icon 0.31%
$97.31
price down icon 0.33%
$31.50
price down icon 0.66%
$91.46
price down icon 0.15%
biotechnology ONC
$307.02
price up icon 0.32%
$166.55
price down icon 16.08%
Kapitalisierung:     |  Volumen (24h):